Okazaki M, Maruyama S, Masuda A, Yamamoto K. Camptothecin derivative- and HSP90 inhibitor-bonded polymers, and antitumor agents containing them WO2015125640. (2015).
Wang WC, Xia LH, Huang WW, Huang Y, Zhao XJ, Li QY, et al. Camptothecin derivative, its preparation method and application CN108484623. (2018).
Wang W, Guo WY, Zhang L, et al. Injection containing camptothecin derivative, and injection liquid, preparation and use thereof WO2017045603. (2017).
Langecker P, Steiert M, Hino T, Scicinksi J, Paulvannan K. Camptothecin derivatives and uses thereof WO2017156183. (2017).
Beretta GL, Gatti L, Perego P, Zaffaroni N. Camptothecin resistance in cancer: Insights into the molecular mechanisms of a DNA-damaging drug. Curr Med Chem 2013; 20(12): 1541-65.
Avinash B. Conjugated anti-proliferative drug nano-particles and process for preparation thereof WO2017221270. (2017).
Zhou F, Han J, Fu JJ, Fei YY, Zhang Y. Bile acid-Xenopus laevis glucagon-like peptide-1 conjugate peptide and application thereof CN107698677. (2018).
Li QY, Zhao TF, Zu YG, et al. Camptothecin 20-position bile acid derivative and preparation method thereof CN102516347. (2012).
Li QY, Zhang BY, Zhao TF, et al. Camptothecin 20-position bile acid derivative and preparation method thereof CN102492010. (2012).
Li QY, Zu YG, Zhao TF, et al. Camptothecin 10-position bile acid derivative and preparation method thereof CN102532237. (2012).
Li QY, Gao Y, Zu YG, et al. Camptothecin 10-position bile acid derivative and preparation method thereof CN101967172. (2011).
Leow CC, Dimasi N, Coffman K, et al. Preparation of bispecific anti-human VEGF-A and angiopoietin 2 antibodies for reduction of angiogenesis and therapy of cancer with reduced thromboembolic and/or renal toxicity WO2018037000. (2018).
Bicknell R, Khan KA. Modulators of the interaction of CD248 with its ligand multimerin 2 (MMRN2) for use as angiogenesis modulators and anticancer WO2018154307. (2018).
Bumcrot D, Toudjarska I, Sah DW. Lipid formulated compositions and methods for inhibiting expression of EG5 and VEGF genes WO2011034798. (2011).
Ichim CV. Methods and compositions for treatment of cancer by inhibition of NR2F2 US20150297627. (2015).
Salcedo TW, Rosen CA, Albert VR, Humphreys R, Vaughan T. Antibodies that immunospecifically bind to TRAIL receptor TR7 for cancer diagnosis and therapy US20050214207. (2005).
Baylin SB, Pardoll DM, Topalian SL. Cancer therapy via a combination of epigenetic modulation and immune modulation WO2015035112. (2015).
Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007; 35(4): 495-516.